In mouse tumor models, particularly in the absence of an adaptive immune system, we reported that IL-33 promoted the expansion of active ILC2s via ST2 that facilitated tumor growth by diminishing NK cell activation and tumor-killing [150]. This evidence concerns the gene IL33 and neoplasm.